Navigation Links
Trial Drug Shows Preliminary Promise Against Ovarian Cancer
Date:8/22/2011

SUNDAY, Aug. 21 (HealthDay News) -- An experimental drug that's shown promise against ovarian cancer caused by mutations in the BRCA1 or BRCA2 genes may also be effective against ovarian cancer not caused by those gene mutations, according to a new study.

Olaparib blocks the activity of a protein called poly ADP ribose polymerase (PARP). Both PARP and BRCA proteins are involved in DNA repair. Clinical trials of olaparib in patients with BRCA 1 and 2 mutations have yielded promising results, the study authors noted.

In the new study, Canadian researchers say they're the first to show that olaparib reduces tumor size in patients with non-hereditary (sporadic) ovarian cancer, which is much more common than BRCA-mutated ovarian cancers.

The phase 2 trial included 65 ovarian cancer patients who received 400 milligrams of olaparib twice daily for four weeks. Measurable tumor shrinkage was seen in 41 percent of patients with BRCA mutations and in 24 percent of those without BRCA mutations, the researchers said.

The study was published online Aug. 21 in The Lancet Oncology.

Side effects were described as mild and included fatigue, nausea, vomiting and decreased appetite, study lead author Karen Gelmon, of the B.C. Cancer Agency in Vancouver, and colleagues said in a news release from the journal.

"This finding not only suggests new therapeutic possibilities for women with this aggressive type of ovarian cancer, but also importantly confirms the hypothesis that subpopulations of patients with common sporadic tumors can be targeted effectively with PARP inhibitor therapy," Dr. Melinda Telli, of Stanford University School of Medicine, wrote in an accompanying editorial.

Another expert agreed. Dr. Stephanie V. Blank is an assistant professor in clinical gynecologic oncology at NYU School of Medicine. She said: "It is extremely exciting that an agent as promising as olaparib can be effective in a broad
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Superdrug Against Range of Viruses Shows Promise in Animal Trials
2. New TB vaccine enters proof-of-concept trial in people living with HIV
3. ESC announces review of Atrial Fibrillation Guidelines
4. University Hospitals Case Medical Center to begin clinical trial on experimental anti-TB drug
5. New clinical trial to examine medication to treat social withdrawal in Fragile X and autism
6. VOICE study will continue as it considers what action to take after results of 2 trials
7. Covidien supports NOSCAR US multicenter human trial
8. Amrubicin improved response rate and progression-free survival vs. topotecan in Phase III trial
9. Patient Disparities Seen in Lung Cancer Drug Trials
10. Women, elderly, minorities poorly represented in lung cancer drug trial data submitted to US FDA
11. Massage eases low back pain in randomized controlled trial
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Trial Drug Shows Preliminary Promise Against Ovarian Cancer
(Date:8/28/2015)... IL (PRWEB) , ... August 28, 2015 , ... With ... benefit concert returned for the second year to the Adams County Fairgrounds in Mendon, ... was held to raise money to support music education in the underfunded school districts ...
(Date:8/28/2015)... ... ... The 6th Annual Survivor in the City, Chicago silent auction and cocktail ... its cadre of widespread support—an official letter of support and gratitude from the Mayor ... and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain Aneurysm Foundation ...
(Date:8/28/2015)... ... ... Frequentz ” was featured on NewsWatch as part of its monthly AppWatch, which takes ... and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the app ... from beginning to end. , Businesses benefit greatly from having the ability to track ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Veterans Award, honoring military veterans leading in business. Mr. Troy Mizell, Chairman ... , The inaugural Nashville Business Journal's 2015 Veterans Awards will recognize Nashville military ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for Plastic Surgery ... first and only nonsurgical product approved by the Food and Drug Administration to eliminate ... and Dr. William Koenig are among the premier cosmetic surgeons in Rochester ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3
... closed, American cardiologists say , , WEDNESDAY, July 2 (HealthDay ... to adrenaline did not improve survival among people who ... American cardiologists said the finding does not rule out ... report comes from a group, primarily French, that several ...
... 2 Hanger Orthopedic,Group, Inc. (NYSE: HGR ... Poor,s,Rating Services revised its outlook for Hanger Orthopedic ... Hanger,s corporate credit,rating at "B." "The outlook revision ... an improved financial risk profile," said,Standard & Poor,s ...
... medicine specialist, John Albright, MD, will join three other physicians as ... Fame inductee. , ... Orlando, Florida (PRWEB) July 2, ... will join three other physicians as a 2008 American Orthopaedic ...
... Ambulatory Services of,America, Inc. announced the acquisition of ... from Affiliated Hospitals Dialysis Center.,Affiliated Hospitals Dialysis Center ... and St. John,s Mercy Health System. Prior,to the ... 300 patients,through the three outpatient dialysis centers and ...
... Larry Minnix, President & CEO, American Association of,Homes ... of the Medicare Therapy,Caps Exceptions Process, WASHINGTON, ... Minnix, President & CEO, American Association of Homes ... the Medicare Therapy Caps,Exceptions Process:, "Medicare beneficiaries ...
... Ambulatory Services of,America, Inc. announced the formation of ... to provide outpatient radiation oncology services. ROSA,of North ... Radiation,Oncology Services of America, and some of the ... North Dallas will own and operate Northpoint,Cancer Center ...
Cached Medicine News:Health News:Two-Drug Treatment Didn't Improve Cardiac Arrest Survival Rates 2Health News:Two-Drug Treatment Didn't Improve Cardiac Arrest Survival Rates 3Health News:Hanger Orthopedic Group, Inc. Receives Positive Outlook from Standard & Poor's Rating Services 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 3Health News:Ambulatory Services of America, Inc. Announces the Acquisition of Dialysis Operations in St. Louis, Missouri 2Health News:AAHSA Statement: Therapy Caps Ration Care 2Health News:Ambulatory Services of America, Inc. Announces Joint Venture to Operate Radiation Oncology Facility in Dallas, Texas 2
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ... (NASDAQ: MYL ) shareholder vote regarding its planned ... of Mylan,s offer to Perrigo shareholders have always been, ... careful reflection of the value available to Perrigo shareholders, ... Mylan has allowed its shareholders to consider," said ...
(Date:8/28/2015)... The report "Eubiotics Market by Type (Probiotics, Prebiotics, ... Aquaculture), & by Region ( North America , ... and Rest of the World) - Global Trends and Forecast ... was valued at USD 4.62 Billion in 2014 and is ... CAGR of 7.4% from 2015 to 2020. ...
(Date:8/27/2015)... Mass. , Aug. 27, 2015  A ... the KSSTA Knee Journal, compared the Arthrosurface HemiCAP® ... Arthroplasty design, versus an "onlay" design implant for ... similar improvements in function and pain scores, none ... progression of osteoarthritis (OA). However, 53% of the ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... fundamental traits of a,tumor – how it avoids ... according to researchers from the,University of Southern California. ... cancers, indicate that,a technique for determining a tumor’s ... cancers. , ,In the July 1 issue ...
... - Nymox,Pharmaceutical Corporation (NASDAQ: NYMX) today announced ... of NX-1207 for,benign prostatic hyperplasia (BPH) will ... the American Urological Association Meeting in,Boston in ... clinical,research investigators from U.S. clinical trials of ...
Cached Medicine Technology:Researchers Discover Method for Identifying How Cancer Evades the,Immune System 2Researchers Discover Method for Identifying How Cancer Evades the,Immune System 3Clinical Data From Nymox BPH Drug To Be Presented at American,Urological Association Meeting 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... MacularProtect delivers levels of nutrients ... and macular health in the ... The National Eye Institute. MacularProtect ... lutein, an antioxidant found to ...
Oculair (re-formulated Syntrx Complete) is a potent full-spectrum multiple vitamin/mineral/antioxidant dietary supplement that supports the normal aging process. It is designed to reflect the most re...
Medicine Products: